YCBD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.727

Open

0.690

VWAP

0.71

Vol

518.35K

Mkt Cap

7.37M

Low

0.690

Amount

366.23K

EV/EBITDA(TTM)

--

Total Shares

10.50M

EV

3.65M

EV/OCF(TTM)

--

P/S(TTM)

0.21

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Show More

Events Timeline

(ET)

2025-12-19

15:30:00

cbdMD Trading Resumes

2025-12-19

15:30:00

cbdMD Enters Securities Purchase Agreements Issuing 1M Convertible Preferred Shares

2025-12-19

14:10:00

cbdMD Trading Halted, News Pending

2025-11-21 (ET)

2025-11-21

08:32:38

cbdMD projects FY25 revenue between $19.1M and $19.3M, down from $19.5M last year

2025-10-09 (ET)

2025-10-09

10:05:50

cbdMD's Herbal Oasis Forms Distribution Alliance with Bevtalk

2025-04-22 (ET)

2025-04-22

10:19:29

cbdMD announces automatic conversion of shares, 1-for-8 reverse stock split

2025-01-03 (ET)

2025-01-03

16:12:52

cbdMD discloses NYSE listing compliance notice

News

seekingalpha

02-17seekingalpha

cbdMD Q1 Earnings Beat Expectations with Revenue of $5M

seekingalpha

02-15seekingalpha

cbdMD to Announce Q1 Earnings on February 16

Newsfilter

02-12Newsfilter

cbdMD to Host Conference Call on Q1 Financial Results

Newsfilter

01-29Newsfilter

cbdMD Integrates Bluebird Assets to Enhance Compliance

Newsfilter

01-14Newsfilter

cbdMD Acquires Bluebird Botanicals, Strengthening Long-Term Growth Foundation

seekingalpha

01-14seekingalpha

cbdMD Acquires Bluebird Botanicals Assets, Strengthening Revenue Base

1 Analyst Rating

Wall Street analysts forecast YCBD stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Maxim

Buy

downgrade

$3 -> $2

AI Analysis

2025-08-20

Reason

Maxim

Price Target

$3 -> $2

AI Analysis

2025-08-20

downgrade

Buy

Reason

Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.

Maxim

Buy

downgrade

$16 -> $3

2025-05-22

Reason

Maxim

Price Target

$16 -> $3

2025-05-22

downgrade

Buy

Reason

Valuation Metrics

The current forward P/E ratio for cbdMD Inc (YCBD.A) is -5.27, compared to its 5-year average forward P/E of -3.71. For a more detailed relative valuation and DCF analysis to assess cbdMD Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.71

Current PE

-5.27

Overvalued PE

4.10

Undervalued PE

-11.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-53.25

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

131.59

Undervalued EV/EBITDA

-238.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.81

Current PS

0.56

Overvalued PS

1.82

Undervalued PS

-0.21

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

bullish penny stock monday

Intellectia · 65 candidates

Region: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00One Day Rise Prob: >= 60Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Battalion Oil Corp

73.07M

Flux Power Holdings Inc

32.22M

Auddia Inc

3.03M

Guardforce AI Co Ltd

11.66M

Ziprecruiter Inc

196.95M

cbdMD Inc

9.97M

stock to increase price today and tomorrow

Intellectia · 116 candidates

Price Change Pct: >= $0.01Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 65One Day Predict Return: >= 1.0%

Ticker

Name

Market Cap$

PEDEVCO Corp

59.31M

First BanCorp

3.52B

Jerash Holdings (US) Inc

41.91M

Ryman Hospitality Properties Inc

6.43B

Kestrel Group Ltd

92.75M

Sify Technologies Ltd

1.08B

Stock 1 day prediction under a dollar

Intellectia · 2 candidates

Price: $0.10 - $1.00Rsi Category: moderate, overboughtOne Day Rise Prob: >= 55One Day Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 300,000

Ticker

Name

Market Cap$

Sow Good Inc

6.74M

cbdMD Inc

9.69M

best penny stocks to buy short term

Intellectia · 30 candidates

Market Cap: <= 1000.00MRegion: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: $5.00 - $50.00One Week Rise Prob: >= 60Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

NIU Technologies

265.08M

Greenland Technologies Holding Corp

18.96M

AMC Entertainment Holdings Inc

759.16M

Enlivex Therapeutics Ltd

275.36M

Estrella Immunopharma Inc

60.95M

Protalix Biotherapeutics Inc

232.42M

us stocks under 5$ marked to buy now

Intellectia · 85 candidates

Price: $0.50 - $5.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Perspective Therapeutics Inc

281.74M

cbdMD Inc

10.92M

Context Therapeutics Inc

239.80M

Acumen Pharmaceuticals Inc

157.49M

Allogene Therapeutics Inc

413.50M

Montauk Renewables Inc

247.53M

low float high volume

Intellectia · 49 candidates

Region: USVolume: >= 500,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

FAT Brands Inc

5.25M

Aprea Therapeutics Inc

5.57M

FAT Brands Inc

27.81M

cbdMD Inc

10.92M

Lixiang Education Holding Co Ltd

6.50M

Kaixin Holdings

29.77M

Whales Holding YCBD

Trading Trends

People Also Watch

Frequently Asked Questions

What is cbdMD Inc (YCBD) stock price today?

The current price of YCBD is 0.702 USD — it has increased 4.77

What is cbdMD Inc (YCBD)'s business?

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

What is the price predicton of YCBD Stock?

Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is cbdMD Inc (YCBD)'s revenue for the last quarter?

cbdMD Inc revenue for the last quarter amounts to 5.02M USD, decreased -1.89

What is cbdMD Inc (YCBD)'s earnings per share (EPS) for the last quarter?

cbdMD Inc. EPS for the last quarter amounts to -0.04 USD, decreased -97.69

How many employees does cbdMD Inc (YCBD). have?

cbdMD Inc (YCBD) has 42 emplpoyees as of March 12 2026.

What is cbdMD Inc (YCBD) market cap?

Today YCBD has the market capitalization of 7.37M USD.